# Treatment -Resistant Neovascular Age-Related Macular Degeneration

> **NCT02332941** · PHASE1 · COMPLETED · sponsor: **Washington University School of Medicine** · enrollment: 5 (estimated)

## Conditions studied

- Macular Degeneration

## Interventions

- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT02332941
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-08
- **Primary completion:** 2015-06
- **Final completion:** 2015-06
- **Target enrollment:** 5 (ESTIMATED)
- **Last updated:** 2015-06-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02332941

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02332941, "Treatment -Resistant Neovascular Age-Related Macular Degeneration". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT02332941. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*